Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
A comprehensive database inquiry at our institutions identified 11 patients with echocardiogram-documented idiopathic cardiomyopathy that post-dated a diagnosis of either polycythemia vera or essential thrombocythemia. Anagrelide therapy was temporally associated with the particular complication in 6 patients, all of whom experienced symptomatic and/or objective improvement after drug discontinuation.
Jurgens
Donald J
DJ
Moreno-Aspitia
Alvaro
A
Tefferi
Ayalew
A
D009202:Cardiomyopathies / Q000139:chemically induced*; D005260:Female; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects*; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide